TTI-101 is a novel small molecule STAT3 inhibitor, and is in a Phase I clinical trial examining pharmacokinetics and compound safety in advanced breast cancer patients as well as patients with unresectable solid tumors (NCT03195699). This evidence concerns the gene STAT3 and breast cancer.